Report : Middle East & Africa Coagulation Analyzers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others)
At 5.0% CAGR, the Middle East & Africa Coagulation Analyzers Market is speculated to be worth US$ 259.47 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa coagulation analyzers market was valued at US$ 193.71 million in 2022 and is expected to reach US$ 259.47 million by 2028, registering a CAGR of 5.0% from 2022 to 2028. Increasing prevalence of blood disorders and rising cardiovascular diseases are the critical factors attributed to the Middle East & Africa coagulation analyzers market expansion.
A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to measure blood platelet levels and thrombolin and thromboplastin levels accurately. Thus, the increasing prevalence of blood disorders is driving the Middle East & Africa coagulation analyzers market growth.
On the contrary, high costs and stringent regulations associated with coagulation analyzers hampers the Middle East & Africa coagulation analyzers market.
Based on product, the Middle East & Africa coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory segment held 67.6% share of Middle East & Africa coagulation analyzers market in 2022, amassing US$ 130.94 million. It is projected to garner US$ 169.23 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on test, the Middle East & Africa coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held 52.7% share of Middle East & Africa coagulation analyzers market in 2022, amassing US$ 102.18 million. It is projected to garner US$ 136.93 million by 2028 to expand at 5.0% CAGR during 2022–2028.
Based on technology, the Middle East & Africa coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies. The optical technology segment held 60.4% share of Middle East & Africa coagulation analyzers market in 2022, amassing US$ 117.07 million. It is projected to garner US$ 158.11 million by 2028 to expand at 5.1% CAGR during 2022–2028.
Based on end users, the Middle East & Africa coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others. The clinical laboratories segment held 59.7% share of Middle East & Africa coagulation analyzers market in 2022, amassing US$ 115.70 million. It is projected to garner US$ 156.71 million by 2028 to expand at 5.2% CAGR during 2022–2028.
Based on country, the Middle East & Africa coagulation analyzers market has been categorized into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Our regional analysis states that Saudi Arabia captured 34.6% share of Middle East & Africa coagulation analyzers market in 2022. It was assessed at US$ 66.94 million in 2022 and is likely to hit US$ 90.78 million by 2028, exhibiting a CAGR of 5.2% during the forecast period.
Key players dominating the Middle East & Africa coagulation analyzers market are Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc, among others.
- In March 2022; Mindray Launched the BC-700 Series, a Compact, Integrated CBC & ESR Hematology Analyzer for Small-to-mid Sized Labs. It incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com